Ruxolitinib for myelofibrosis therapy: Current context, pros and cons

Research output: Contribution to journalArticle

8 Citations (Scopus)
Original languageEnglish (US)
Pages (from-to)1449-1451
Number of pages3
JournalLeukemia
Volume26
Issue number7
DOIs
StatePublished - Jul 2012

Fingerprint

Pyrazoles
Janus Kinases
Primary Myelofibrosis
Therapeutics
INCB018424

ASJC Scopus subject areas

  • Hematology
  • Cancer Research
  • Anesthesiology and Pain Medicine

Cite this

Ruxolitinib for myelofibrosis therapy : Current context, pros and cons. / Pardanani, Animesh D.

In: Leukemia, Vol. 26, No. 7, 07.2012, p. 1449-1451.

Research output: Contribution to journalArticle

@article{614529f8daac4875bf0fb90cd86bdb2f,
title = "Ruxolitinib for myelofibrosis therapy: Current context, pros and cons",
author = "Pardanani, {Animesh D}",
year = "2012",
month = "7",
doi = "10.1038/leu.2012.21",
language = "English (US)",
volume = "26",
pages = "1449--1451",
journal = "Leukemia",
issn = "0887-6924",
publisher = "Nature Publishing Group",
number = "7",

}

TY - JOUR

T1 - Ruxolitinib for myelofibrosis therapy

T2 - Current context, pros and cons

AU - Pardanani, Animesh D

PY - 2012/7

Y1 - 2012/7

UR - http://www.scopus.com/inward/record.url?scp=84863781835&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84863781835&partnerID=8YFLogxK

U2 - 10.1038/leu.2012.21

DO - 10.1038/leu.2012.21

M3 - Article

C2 - 22285996

AN - SCOPUS:84863781835

VL - 26

SP - 1449

EP - 1451

JO - Leukemia

JF - Leukemia

SN - 0887-6924

IS - 7

ER -